MINI FUTURE OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 01:07:09 18/05/2024 am IST | ||
| 22.45 EUR | -2.35% |
|
| Current month | -18.89% | ||
| 1 month | -19.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 22.45 | -2.35% |
| 16/24/16 | 22.99 | -1.16% |
| 15/24/15 | 23.26 | -4.04% |
| 14/24/14 | 24.24 | +0.41% |
| 13/24/13 | 24.14 | -2.86% |
Delayed Quote Börse Stuttgart
Last update May 18, 2024 at 01:07 am IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB9J7S |
| ISIN | DE000JB9J7S2 |
| Date issued | 08/01/2024 |
| Strike | 689.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 24.72 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.97 € |
|---|---|
| Lowest since issue | 22.45 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Certificates
- Certificat
